July 22, 2019
Article
On July 20, 2018, the FDA approved ivosidenib (Tibsovo) as a treatment option for adult patients with relapsed/refractory acute myeloid leukemia, specifically with a mutation in the IDH1 gene.
May 16, 2019
On July 20, 2018, Pfizer Inc announced the FDA approval of filgrastim-aafi (Nivestym), a biosimilar to Amgen’s biologic Neupogen (filgrastim).
April 17, 2019
Accreditation helps pharmaceutical manufacturers narrow the potential pharmacies it may include in a specialty network offering.
March 15, 2019
Celgene Corporation’s lenalidomide (Revlimid) is a targeted therapy that stops the growth of myeloma cells in the bone marrow.
January 15, 2019
With this technology interface, the health care system could experience enhanced communication, efficiency, and regulatory compliance, which makes patient safety the ultimate benefit.